Yumanity Therapeutics (FRA:8IY) Change In Payables And Accrued Expense : €-3.90 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Change In Payables And Accrued Expense?

Yumanity Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2022 was €-1.11 Mil. It means Yumanity Therapeutics's Accounts Payable & Accrued Expense declined by €1.11 Mil from Jun. 2022 to Sep. 2022 .

Yumanity Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2021 was €-7.56 Mil. It means Yumanity Therapeutics's Accounts Payable & Accrued Expense declined by €7.56 Mil from Dec. 2020 to Dec. 2021 .

Yumanity Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Yumanity Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Change In Payables And Accrued Expense Chart

Yumanity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Change In Payables And Accrued Expense

1.06

0.53

-7.56

Yumanity Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Payables And Accrued Expense	Get a 7-Day Free Trial							0.66	0.27	-2.19	-0.87	-1.11

Yumanity Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.90 Mil.

Yumanity Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Yumanity Therapeutics (FRA:8IY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

40 Guest Street, Suite 4410, Boston, MA, USA, 02135

Website

https://www.yumanity.com

Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines